| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
02-09-2017, 10:19 AM
|
#1 | ||
|
|||
|
Member
|
Great news for those suffering from OFF periods
Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods in people with Parkinson’s disease taking an oral carbidopa / levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms. The Company plans to file a New Drug Application (NDA) in the United States by the end of the second quarter of 2017. Acorda Therapeutics Inc - Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-3 1 |
||
|
 Reply With Quote
|
| "Thanks for this!" says: |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| ALS treatment yields positive phase II results | ALS News & Research | |||
| Positive Phase 2/3 results for Extended Release Amantadine | Parkinson's Disease | |||
| Adamas Pharmaceuticals To Report Positive Phase 2/3 Results | Parkinson's Disease | |||
| Ceregene announces positive phase 1 results ... | Parkinson's Disease | |||
| Positive Results of Phase 3 Study of Fampridine-SR on walking | Multiple Sclerosis | |||
Help for those with serious OFF periods - Positive Phase 3 Results for CVT-301
Threaded Mode